Theta-Burst Stimulation for Parkinson's Disease with Mild Cognitive Impairment

This trial investigates whether intermittent theta burst stimulation (iTBS), a special type of brain stimulation, can help people with Parkinson's disease who also experience mild memory or thinking problems. The treatment is non-invasive, meaning it doesn’t involve surgery, and aims to improve brain function safely. Suitable participants have been diagnosed with Parkinson's disease, notice mild difficulties with memory or thinking, and have been stable on their medications for at least 30 days. As an unphased trial, this study offers an opportunity to contribute to groundbreaking research that could enhance treatment options for Parkinson's patients.

Studies have shown that intermittent theta-burst stimulation (iTBS) is generally safe and well-tolerated. Previous research indicates that no serious side effects occurred in earlier studies of iTBS. This treatment has been used for conditions like depression and has FDA approval for that purpose, suggesting its safety. Possible side effects include mild headaches, scalp irritation, or tiredness, but these are usually temporary and not severe. Overall, iTBS appears to be a promising and safe treatment option.¹²³⁴⁵

Most treatments for Parkinson's disease with mild cognitive impairment, like medications and deep brain stimulation, primarily aim to manage motor symptoms or enhance dopamine activity. However, accelerated intermittent theta-burst stimulation (iTBS) represents an innovative approach that targets the brain's right superior parietal lobule using magnetic pulses to potentially improve both motor and cognitive functions. Researchers are excited because iTBS is non-invasive and can deliver rapid results, with sessions completed in just a few days. This treatment might offer a new, efficient way to address cognitive impairments, which are often harder to treat with existing options.

Research has shown that intermittent theta-burst stimulation (iTBS) can assist individuals with mild memory and thinking problems. Earlier studies demonstrated improved memory and cognitive skills in patients after receiving iTBS. This treatment delivers quick bursts of energy to specific brain areas, enhancing communication between brain cells. It is considered safe and has shown promise in improving cognitive abilities. In this trial, participants will receive accelerated iTBS targeting the right superior parietal lobule. Although more research is needed specifically for Parkinson's disease with mild memory issues, early results are encouraging.